Moreover, a systemic treatment would not be expected to interfere with the action of antibodies against SARS-CoV-2 because the MD simulations show that heparin does not interact with the main regions targeted by antispike antibodies (33): it does not shield either the RBm or the RBD ...
The pharmacological effect of calcium heparin is similar with that of Heparin sodium salt. However, the role of anti-clotting factor II a slightly stronger; the role of anti-Factor Xa is weak. Calcium heparin also has pharmacological effects are such as adjusting blood lipid, anti-inflammatory,...
Meuleman: Pharmacological Profile of the Chemically Synthesized Antithrombin III Binding Fragment of Heparin (pentasaccharide) in Rats. Thromb. Haemost. 63, 265–270 (1990). 59. Meuleman, D.G., P.M.J. Hobbelen, T.G. van Dinther, G.M.T. Vogel, C.A.A. van Boeckel, and H.C.T. ...
Such alterations are not expected to substantially affect apparent molecular weight as determined by polyacrylamide gel electrophoresis or isoelectric point. Conservative substitutions also include substituting optical isomers of the sequences for other optical isomers, specifically D amino acids for L amino ...
This may be achieved by administering a single composition or pharmacological formulation that includes both agents, or by administering two distinct compositions or formulations, at the same time, wherein one composition includes the mutant human factor IX therapeutic composition and the other includes ...
The search for new solutions to overcome the resistance of malignant cells to pharmacological agents is being actively pursued. Another serious problem is immunosuppression caused both by the tumor cells themselves and by antitumor drugs. Of great interest in this context is heparin, a biomolecule ...
Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J. Thromb. Haemost. 2009, 7, 1143–1151. [Google Scholar] [CrossRef] [PubMed] Viskov, C.; Elli, S.; Urso, E.; Gaudesi, D.; Mourier, P.; Herman, F....
Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): Formulation development, characterization and pharmacological evaluation. J. Control. Release 2018, 290, 165–179. [Google Scholar] [CrossRef] Kumar, S.; Kesharwani, S.S.; Mathur, H.; Tyagi, M.; Bhat, ...